NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Thanks Slave1. I had a family crisis today and could not listen to the ASM. I took your meeting minutes and ran it through AI for a detailed summary:

Northwest Biotherapeutics (NWBO) – Annual Shareholder Meeting Summary (Dec 29, 2025)
(Based strictly on the transcript from InvestorsHub)

1. Formal Meeting Proceedings
Attendance & Setup
-Linda Powers presided as Chair, CEO, CFO, and CAO.
-Directors present: Dr. Al Boynton, Pat Sarma (virtually), Dr. Navid Malik, Ambassador Cofer Black, Dr. Monica Bosch (virtually).
-Inspector of Elections: Thomas Cooper (Computershare).
-Investor Relations: Dave Innes (stepping in after Les Goldman’s passing).

Quorum & Voting Mechanics
-1.19B shares represented out of 1.54B outstanding — quorum established.
-Preferred C shares carry 25 votes each.
-Proxies largely submitted in advance; ballots collected only from registered shareholders present.

Items Voted On — All Approved
-Election of Pat Sarma as Class II Director (term through 2027).
-Ratification of Cherry Bekaert LLP as auditor for FY 2025.
-Increase in authorized shares from 1.7B ? 2.6B.
-Advisory approval of executive compensation.
-Final results to be filed in an 8-K within four business days.

2. Informal Q&A Session (˜45 minutes)
Linda Powers grouped dozens of shareholder questions into four major categories:

Category 1 — Regulatory Pathway (MHRA, FDA, Canada)
MHRA Review Status
-NWBO is in active cycles of questions, clarifications, and data requests.
-MHRA is devoting “enormous” resources to the application — advisors confirm this is unusual and positive.
-NWBO cannot predict timing; other companies are also stuck in multi-year review cycles.

Why the UK First?
-Long UK history:
--First-ever PIM (Promising Innovative Medicine) designation.
--Included in national priority clinical trial portfolio.-
--Access to the 150-day accelerated pathway.

Next Steps After UK
-File in Canada (similar format to UK).
-File in US (different format).

Reason for sequential filings:
-Each application is intensive and expensive (~$12M/year in consultants).
-Priority is securing first approval.

Positive Industry Trends
-MHRA draft guidance supporting external controls becoming permanent.
-Regulators (including FDA) increasingly embracing real-world evidence — important because NWBO has hundreds of compassionate-use patients.

Launch Strategy
-Launch immediately upon approval, not waiting for reimbursement.
-UK brain cancer surgeries are concentrated in ~10 centers, making rollout manageable.
-Grade B suites alone are sufficient for initial launch; Grade C suite not required for approval or launch.
-Launch financing expected to use non-dilutive structures (royalty or non-convertible debt).

Category 2 — Clinical Programs (DCVax-Direct, Roswell/Pittsburgh, Compassionate Use)
DCVax-Direct
-Manufacturing is fully ready; tech transfer and validation completed in spring 2025.
-IND package’s CMC section is already written.

Phase 2 indication selected:
-Non-brain solid tumor, “below the neck.”
-Lead institutions in US and UK are “jumping up and down” to start.
-NWBO is delaying initiation due to cost tradeoffs:
-Priority spending is MHRA approval + Sawston buildout.

Roswell Park & Pittsburgh IP Portfolio
-Represents 25 years of dendritic cell research by Dr. Kalinski.
-Academic trials temporarily paused due to Kalinski’s move back to Pittsburgh — no impact on NWBO’s license.

NWBO’s first company-sponsored trial:
-Ovarian cancer combination trial using polarized Alpha-DC1 cells.
-Builds on prior encouraging ovarian cancer data from NWBO’s earlier pilot.

Compassionate Use
-Program ongoing and expanding.
-New doctors and a private hospital chain in discussions.
-Plan to offer compassionate use for most solid tumors in 2026.
-Plan to add DCVax-Direct to compassionate use.

Category 3 — Manufacturing (Sawston, Advent, Pittsburgh, Flaskworks)
Sawston Facility
-Two existing Grade B suites are sufficient for launch.

Process optimization underway:
-More staff,
-Streamlining steps outside B suites,
-Potential two-shift operations.
-Grade C Suite
-Original plan: two large, expensive C suites.

New plan:
-simplified C suite near loading docks — less than half the cost.
-Contractor selected; site prep done; construction expected to start January and finish in ~6 months.
-Even one simplified C suite will have >2× the capacity of both Grade B suites combined.

Equipment Procurement
-Long lead times (10–12 months) and high cost (~$1M per machine).
-Advent secured one new and one nearly new machine at half price and without long delays.

Advent Control
-Advent is a wholly owned subsidiary; NWBO has full control over personnel, processes, and quality systems.
-Pittsburgh Manufacturing

Will manufacture:
Kalinski dendritic cell products,
DCVax-L and DCVax-Direct for trials and compassionate use.
Commercial production will remain at Sawston.

Flaskworks
-Prototype complete; GMP version needed.
-Initial engineering team made unwanted redesigns (too large).
-Two new engineering teams now working on GMP version through first half of 2026.
-Goal: synchronize Flaskworks readiness with Grade C suite readiness.

Category 4 — Business Strategy (Shares, Partnering, Management Expansion)
-Authorized Shares Increase (1.7B ? 2.6B)
-Purpose: flexibility for major financing negotiations.

Powers emphasized:
-No intention to “willy-nilly” issue 900M shares.
-At historical burn rates and share prices, it would take years to use that many shares.
-NWBO intends to prioritize non-dilutive financing.
-Partnering

Regional partnerships:
-NWBO is already in exploratory discussions for a regional deal.
-Patent portfolio maintained globally at ~$1.5M/year to support such deals.

Big Pharma partnerships:
-NWBO is “thrilled” at the prospect.
-Combination trials (e.g., checkpoint inhibitors + DCVax) are viewed as the gateway.
-Management Expansion & Succession

First wave of expansion already lined up:
-Senior managers in clinical, medical, finance, accounting, and operations.
-Currently consultants; will convert to employees upon approval.
-Additional hires and succession planning are active priorities.

Closing
-Meeting adjourned at 2:57 PM.
-Final voting results to be filed in an 8-K within four business days.